Immunology and Allergies

On this page

🛡️ Immunological Foundations: The Pediatric Defense Architecture

Children's immune systems are simultaneously their greatest protectors and potential adversaries, capable of mounting life-saving defenses against pathogens while sometimes turning against harmless proteins in peanuts or pollen. You'll master how pediatric immunity develops its unique architecture, decode the four hypersensitivity mechanisms that drive allergic disease, and build a systematic approach to diagnosis that distinguishes true allergy from mimics. Then you'll command evidence-based management strategies from acute anaphylaxis protocols to the transformative science of immunotherapy that retrains tolerance at the molecular level, equipping you to guide families through one of childhood's most common yet misunderstood conditions.

The immune system's architectural complexity emerges through three critical phases: passive immunity transition (0-6 months), active immunity development (6 months-2 years), and immunological maturation (2-12 years). Each phase carries distinct vulnerabilities and clinical implications that shape pediatric practice.

📌 Remember: MATURED - Maternal antibodies wane (6 months), Active immunity starts, T-cells mature (2 years), Universal responses develop, Recognition improves, Effector functions peak, Durable memory established (12 years)

Immunological Development Phases

  • Passive Immunity Phase (0-6 months)

    • Maternal IgG provides 90% protection against common pathogens
    • Antibody half-life: 21-28 days with steady decline
      • Birth levels: 800-1200 mg/dL IgG
      • Nadir at 3-4 months: 200-400 mg/dL
      • Recovery begins: 6-9 months
    • Secretory IgA from breast milk protects mucosal surfaces
  • Active Immunity Development (6 months-2 years)

    • Primary immune responses emerge with 10-14 day lag time
    • B-cell maturation enables class switching and memory formation
      • IgM responses: 70% adult levels by 12 months
      • IgG subclass development: IgG1/IgG3 first, IgG2/IgG4 delayed
      • Memory B-cell pool: <10% adult capacity until 18 months
  • Immunological Maturation (2-12 years)

    • T-cell repertoire diversification reaches 80% adult complexity
    • Cytokine production patterns mature from Th2-predominant to balanced Th1/Th2
      • IL-4/IL-13 production: 200% adult levels (predisposes to allergies)
      • IFN-γ capacity: 40% adult levels until school age
      • Regulatory T-cell function: 60% efficiency until adolescence
ParameterBirth3 Months6 Months12 Months24 MonthsAdult Level
Total IgG (mg/dL)10003504506508001200
IgM (mg/dL)1525457595120
IgA (mg/dL)58153565200
CD4+ Count (/μL)25002000180015001200800
NK Cell %151210865

💡 Master This: Delayed IgG2 maturation until 24-36 months explains increased susceptibility to encapsulated bacteria (pneumococcus, Haemophilus) in toddlers, necessitating conjugate vaccine strategies that convert T-independent to T-dependent responses.

The complement system follows parallel maturation kinetics, with C3/C4 levels reaching only 60% adult values by 12 months and alternative pathway function remaining 40% deficient until school age. This complement deficiency contributes to recurrent respiratory infections in 25% of healthy toddlers.

Understanding these developmental timelines transforms clinical decision-making, from interpreting infection patterns to optimizing vaccination schedules and recognizing true immunodeficiency versus developmental immaturity.


🛡️ Immunological Foundations: The Pediatric Defense Architecture

🎯 Hypersensitivity Mechanisms: The Allergic Response Arsenal

The Gell-Coombs classification provides the mechanistic framework for understanding allergic diseases, with Type I (immediate) reactions dominating pediatric allergy practice through IgE-mediated mechanisms affecting 8-10% of children globally.

📌 Remember: ACID - Anaphylaxis (Type I), Cytotoxic (Type II), Immune complex (Type III), Delayed (Type IV) - represents the temporal and mechanistic progression of hypersensitivity responses

Type I Hypersensitivity: IgE-Mediated Immediate Reactions

  • Sensitization Phase (Primary Exposure)

    • Allergen processing by dendritic cells within 2-4 hours
    • Th2 differentiation driven by IL-4 and TSLP signals
      • IL-4 production: 10-fold ↑ in atopic children
      • IL-13 levels: 5-fold ↑ correlating with IgE elevation
      • GATA-3 transcription factor: 3-fold ↑ expression
    • IgE class switching requires CD40L-CD40 interaction
      • Peak IgE production: 7-14 days post-exposure
      • IgE half-life: 2-3 days (shortest immunoglobulin)
      • Mast cell binding: >99% IgE bound within 24 hours
  • Effector Phase (Re-exposure)

    • Cross-linking threshold: ≥2 IgE molecules per allergen
    • Degranulation kinetics: 15-30 seconds for preformed mediators
      • Histamine release: 50-80% of cellular stores
      • Tryptase elevation: Peak at 1-2 hours, half-life 2 hours
      • Leukotrienes (LTC4/LTD4): Peak at 5-15 minutes
    • Late-phase reaction: 4-12 hours post-exposure
      • Eosinophil recruitment: 10-100 fold ↑ tissue levels
      • Neutrophil influx: Peak at 6-8 hours
      • Cytokine storm: IL-5, IL-13, TNF-α elevation
MediatorRelease TimePeak EffectDurationClinical Impact
Histamine15-30 sec1-5 min15-30 minVasodilation, bronchospasm
Tryptase15-30 sec1-2 hours4-6 hoursDiagnostic marker
LTC4/LTD45-15 min15-30 min2-4 hoursSustained bronchospasm
PGD25-15 min10-20 min1-2 hoursBronchoconstriction
PAF5-30 min30-60 min2-6 hoursPlatelet aggregation
IL-4/IL-134-6 hours8-12 hours24-48 hoursLate-phase inflammation

Type II Hypersensitivity: Antibody-Dependent Cellular Cytotoxicity

  • Mechanism: IgG/IgM antibodies target cell-surface antigens

    • Complement activation via classical pathway within minutes
    • ADCC (Antibody-Dependent Cellular Cytotoxicity) by NK cells
      • NK cell activation: CD16 (FcγRIII) binding
      • Perforin/granzyme release: Cell death within 2-4 hours
      • Complement-mediated lysis: C5b-9 membrane attack complex
  • Clinical Examples:

    • Drug-induced hemolytic anemia: Penicillin, cephalosporins
    • Transfusion reactions: ABO/Rh incompatibility
    • Autoimmune cytopenias: ITP, AIHA in 2-5% of children

💡 Master This: Type II reactions require hours to days for clinical manifestation, distinguishing them from Type I immediate responses, with hemolysis markers (LDH >500 U/L, haptoglobin <25 mg/dL) confirming antibody-mediated cell destruction.

Understanding hypersensitivity mechanisms enables precise therapeutic targeting, from antihistamines for Type I reactions to immunosuppression for Type II/III diseases, while predicting reaction severity and optimal monitoring strategies.


🎯 Hypersensitivity Mechanisms: The Allergic Response Arsenal

🔍 Allergy Diagnostic Mastery: The Clinical Detective Framework

The diagnostic hierarchy prioritizes clinical history (80% diagnostic accuracy) over laboratory testing, with skin prick tests and serum IgE serving as confirmatory tools rather than screening instruments. Understanding test limitations prevents over-diagnosis in the 15-20% of children with positive tests but no clinical reactivity.

📌 Remember: TRACES - Timing (onset <2 hours), Reproducibility (consistent reactions), Associated symptoms (urticaria/angioedema), Clinical severity (anaphylaxis risk), Environmental factors (seasonal patterns), Specific testing (confirmatory only)

Clinical History: The Diagnostic Foundation

  • Temporal Relationships

    • IgE-mediated reactions: <2 hours onset in >95% of cases
    • Immediate reactions (<30 minutes): High specificity for IgE mechanism
      • Food allergies: Median onset 15 minutes (range 5-60 minutes)
      • Drug allergies: Peak incidence 15-30 minutes post-administration
      • Insect stings: Systemic reactions within 10-20 minutes
    • Delayed reactions (>2 hours): Low probability of IgE involvement
      • Food protein-induced enterocolitis (FPIES): 1-4 hours delay
      • Contact dermatitis: 24-72 hours for Type IV reactions
  • Reproducibility Patterns

    • Consistent reactions: >90% positive predictive value for true allergy
    • Dose-response relationship: Larger exposuresSevere symptoms
      • Threshold doses: Peanut 1-10 mg, Milk 10-100 mg, Egg 10-50 mg
      • Cofactor requirements: Exercise, alcohol, NSAIDs in 5-15%
    • Variable reactions: Consider non-allergic mechanisms or cofactors

Skin Testing: Precision and Pitfalls

  • Skin Prick Test (SPT) Performance

    • Sensitivity: 85-95% for IgE-mediated food allergies
    • Specificity: 30-60% (high false-positive rate in atopic children)
      • Wheal size3 mm (vs. negative control): Positive result
      • Histamine control: ≥3 mm wheal required for valid test
      • Negative control: <1 mm wheal ensures no dermographism
    • Age-related variations:
      • <6 months: Reduced reactivity due to immature mast cells
      • >65 years: Decreased skin reactivity in 40% of patients
  • Intradermal Testing

    • 100-1000 fold more sensitive than SPT
    • Higher false-positive rate: 20-30% in non-allergic individuals
    • Reserved for: Drug allergies, venom sensitivity, negative SPT with strong history
    • Contraindicated: Food allergens (risk of systemic reactions)
Test TypeSensitivitySpecificityFalse Positive RateClinical Application
Skin Prick85-95%30-60%40-70%First-line screening
Intradermal95-99%10-30%70-90%Drug/venom allergy
Serum IgE75-90%50-70%30-50%SPT contraindicated
Component IgE80-95%70-90%10-30%Risk stratification
Basophil Activation85-95%80-95%5-20%Research/complex cases

Serum IgE Testing: Quantitative Insights

  • Total IgE Patterns

    • Normal ranges: Age-dependent with adult levels by 15-20 years
      • 6 months: <15 IU/mL
      • 1 year: <30 IU/mL
      • 5 years: <60 IU/mL
      • 10 years: <90 IU/mL
      • Adults: <100 IU/mL
    • Elevated total IgE: >2 standard deviations suggests atopy
      • Atopic dermatitis: Mean 500-2000 IU/mL
      • Allergic asthma: Mean 200-800 IU/mL
      • Parasitic infections: >1000 IU/mL in endemic areas
  • Specific IgE Interpretation

    • Class 0: <0.35 kU/L (negative)
    • Class 1: 0.35-0.7 kU/L (low positive)
    • Class 2: 0.7-3.5 kU/L (moderate)
    • Class 3: 3.5-17.5 kU/L (high)
    • Class 4: 17.5-50 kU/L (very high)
    • Class 5: 50-100 kU/L (extremely high)
    • Class 6: >100 kU/L (maximum)

💡 Master This: Specific IgE levels correlate with reaction probability but not severity. Peanut IgE >15 kU/L predicts 95% reaction probability, while milk IgE >5 kU/L in toddlers suggests persistent allergy requiring continued avoidance.

Food challenge testing remains the gold standard for definitive diagnosis, with double-blind placebo-controlled challenges providing >95% accuracy but requiring specialized facilities and emergency preparedness for potential anaphylaxis in 5-10% of procedures.

This systematic diagnostic approach prevents both under-diagnosis (missing life-threatening allergies) and over-diagnosis (unnecessary dietary restrictions affecting quality of life and nutrition in growing children).


🔍 Allergy Diagnostic Mastery: The Clinical Detective Framework

⚖️ Allergy Management Strategies: The Therapeutic Command Center

The management pyramid prioritizes allergen avoidance as the foundation (Level 1), pharmacotherapy for symptom control (Level 2), emergency preparedness for severe reactions (Level 3), and immunotherapy for selected cases (Level 4).

📌 Remember: SAFE - Strict avoidance protocols, Action plans for emergencies, Farmacotherapy optimization, Education and emergency training - represents the comprehensive management framework

Level 1: Allergen Avoidance Strategies

  • Food Allergy Avoidance

    • Label reading education: >99% accuracy required for safety
      • "May contain" warnings: 5-10% actual contamination risk
      • Cross-contamination thresholds: <1-10 mg trigger reactions
      • Hidden ingredients: Milk proteins in 20% of "dairy-free" products
    • Cross-contamination prevention:
      • Shared equipment: 1-5 mg allergen transfer typical
      • Airborne exposure: Peanut dust travels >3 meters
      • Kitchen safety: Separate utensils, thorough cleaning protocols
  • Environmental Allergen Control

    • Dust mite reduction: <2 μg/g Der p 1 target level
      • Mattress covers: 85% reduction in allergen exposure
      • Humidity control: <50% relative humidity optimal
      • HEPA filtration: 99.97% particle removal ≥0.3 μm
    • Pet allergen management:
      • Cat allergen (Fel d 1): Persists 6+ months after pet removal
      • Dog allergen (Can f 1): Lower levels but widespread distribution
      • Air purifiers: 60-80% reduction in airborne allergens

Level 2: Pharmacological Management

Medication ClassOnsetDurationEfficacyAge Restrictions
H1 Antihistamines30-60 min12-24 hours70-85% symptom relief>6 months
H2 Antihistamines60-90 min8-12 hours40-60% GI symptoms>12 years
Leukotriene Antagonists2-4 hours24 hours60-75% respiratory>6 months
Mast Cell Stabilizers2-4 weeks6-8 hours50-70% prophylaxis>2 years
Topical Corticosteroids6-12 hours12-24 hours80-95% skin symptoms>3 months
Systemic Corticosteroids4-6 hours12-36 hours90-95% severe reactionsAny age
  • Second-generation preferred: Minimal sedation (<5% vs. 25% first-generation)
    • Cetirizine: Onset 30 minutes, half-life 8 hours
    • Loratadine: Onset 60 minutes, half-life 12-15 hours
    • Fexofenadine: Onset 60 minutes, minimal CNS penetration
  • Dosing optimization:
    • Standard dose: Effective in 60-70% of patients
    • Double dose: Safe and effective in refractory cases
    • Combination therapy: H1 + H2 for GI symptoms
  • Adjunctive Therapies
    • Leukotriene receptor antagonists: Montelukast 4-10 mg daily
      • Respiratory symptoms: 60-75% improvement
      • Exercise-induced reactions: Prophylactic benefit
      • Neuropsychiatric effects: Monitor in 1-2% of patients
    • Mast cell stabilizers: Cromolyn sodium
      • Prophylactic use: 2-4 weeks for full effect
      • Food allergies: Oral cromolyn 200 mg QID
      • Allergic conjunctivitis: Topical drops 4x daily

Clinical Pearl: Combination H1/H2 antihistamine therapy provides superior symptom control in 75% of patients with moderate-severe allergic reactions, particularly for GI symptoms where H2 receptors predominate in gastric mucosa.

Level 3: Emergency Management Protocols

  • Epinephrine Auto-injector Guidelines

    • Dosing: 0.01 mg/kg (maximum 0.5 mg per dose)
      • <15 kg: EpiPen Jr (0.15 mg)
      • 15-30 kg: EpiPen Jr (0.15 mg) or EpiPen (0.3 mg)
      • >30 kg: EpiPen (0.3 mg)
    • Administration technique:
      • Anterolateral thigh: Vastus lateralis muscle
      • Hold 3 seconds: Complete medication delivery
      • Massage site: Enhance absorption
      • Call 911: Transport to emergency department
  • Biphasic Reaction Management

    • Incidence: 5-20% of anaphylaxis cases
    • Timing: 4-12 hours after initial reaction
    • Observation period: Minimum 4-6 hours for mild reactions, 8-24 hours for severe
    • Risk factors: Delayed epinephrine (>30 minutes), severe initial reaction, previous biphasic episodes

💡 Master This: Early epinephrine administration (<30 minutes of symptom onset) reduces fatality risk by >90% and decreases biphasic reaction incidence from 20% to <5%, emphasizing the critical importance of immediate treatment over antihistamine delays.

Comprehensive allergy management transforms high-risk allergic children into confident, well-prepared individuals capable of navigating daily life safely while maintaining normal social and educational development through evidence-based therapeutic strategies.


⚖️ Allergy Management Strategies: The Therapeutic Command Center

🔬 Immunotherapy Revolution: The Tolerance Engineering Protocol

The immunological reprogramming process involves multiple cellular mechanisms: Regulatory T-cell (Treg) expansion, IL-10/TGF-β upregulation, IgG4 blocking antibody production, and mast cell/basophil desensitization. Understanding these pathways optimizes protocol selection and predicts treatment success.

📌 Remember: SHIFT - Suppressive Tregs expand, Helper T-cell balance changes, IgG4 blocking antibodies rise, Functional tolerance develops, Tissue inflammation decreases - represents the immunological transformation during successful immunotherapy

Subcutaneous Immunotherapy (SCIT): The Gold Standard

  • Mechanism and Efficacy

    • Build-up phase: Weekly injections for 3-6 months
      • Starting dose: 1:1,000,000 allergen concentration
      • Dose escalation: 2-3 fold increases per injection
      • Maintenance dose: 5-20 μg major allergen protein
    • Maintenance phase: Monthly injections for 3-5 years
      • Clinical improvement: 60-90% symptom reduction
      • Medication reduction: 50-80% decreased requirements
      • Long-term tolerance: Persists 5-10 years post-treatment
  • Immunological Changes During SCIT

    • Early phase (0-3 months):
      • Basophil desensitization: 50-80% reduced histamine release
      • Mast cell threshold ↑: 10-100 fold increased trigger dose
      • Specific IgE: Initial rise then gradual decline
    • Late phase (6-24 months):
      • IgG4 production: 10-100 fold increase in blocking antibodies
      • Treg expansion: 2-5 foldCD4+CD25+FoxP3+ cells
      • Cytokine shift: IL-10/TGF-β ↑, IL-4/IL-13
Treatment PhaseDurationInjection FrequencyDose RangeClinical ResponseAdverse Reaction Risk
Build-up3-6 monthsWeekly0.1-100 μgMinimal5-15% systemic
Maintenance3-5 yearsMonthly5-20 μg60-90% improvement1-5% systemic
Post-treatment5-10 yearsNoneN/ASustained toleranceNone
  • Advantages and Limitations

    • Safety profile: <1% systemic reaction rate vs. 5-15% with SCIT
    • Convenience: Home administration after initial supervision
    • Efficacy: 60-80% of SCIT effectiveness for respiratory allergies
      • Grass pollen: 25-30% symptom reduction
      • House dust mite: 20-25% improvement
      • Tree pollens: 30-40% benefit
  • SLIT Protocols

    • Daily dosing: 300-2000 IR (Index of Reactivity) units
    • Treatment duration: 3-5 years for optimal results
    • Sublingual retention: 2-3 minutes before swallowing
    • Food restrictions: Avoid eating 30 minutes pre/post dose

Clinical Pearl: Oral immunotherapy (OIT) for food allergies achieves desensitization in 60-80% of patients but requires lifelong daily allergen consumption to maintain tolerance, with 15-20% experiencing persistent GI symptoms requiring treatment discontinuation.

Epicutaneous Immunotherapy (EPIT): The Emerging Frontier

  • Novel Delivery System

    • Patch-based allergen delivery through intact skin
    • Langerhans cell targeting in epidermis
    • Lower systemic exposure: Reduced anaphylaxis risk
    • Pediatric applications: Suitable for young children (4+ years)
  • Clinical Trial Results

    • Peanut EPIT: 35-50% achieve 300 mg tolerance threshold
    • Milk EPIT: 40-60% reach 1000 mg consumption goal
    • Safety profile: <2% systemic reactions, mild local skin irritation

💡 Master This: Immunotherapy success requires patient selection based on specific IgE levels (<50-100 kU/L optimal), clinical severity (moderate reactions preferred), and compliance capacity (>90% adherence essential), with component-resolved diagnostics predicting treatment response in 80-90% of cases.

Precision immunotherapy protocols tailored to individual allergen profiles and clinical phenotypes represent the future of allergy treatment, offering curative potential rather than symptomatic management for the growing population of allergic children worldwide.


🔬 Immunotherapy Revolution: The Tolerance Engineering Protocol

🎯 Clinical Mastery Arsenal: The Allergy Expert's Toolkit

Essential Clinical Algorithms

📌 Remember: MASTER - Mechanisms understood, Algorithms memorized, Severity assessed, Treatment optimized, Emergencies prepared, Results monitored - represents the complete clinical competency framework

  • Rapid Allergy Assessment Protocol

    • History taking: <5 minutes for key elements
      • Timing: <2 hours = IgE-mediated (95% specificity)
      • Reproducibility: Consistent = True allergy (90% PPV)
      • Severity: Anaphylaxis = High-risk (Epinephrine required)
    • Physical examination: Focus on target organs
      • Skin: Urticaria, angioedema, atopic dermatitis
      • Respiratory: Wheeze, stridor, oxygen saturation
      • Cardiovascular: Hypotension, tachycardia, capillary refill
  • Emergency Severity Grading

    • Grade 1 (Mild): Skin symptoms only
    • Grade 2 (Moderate): GI or respiratory involvement
    • Grade 3 (Severe): Cardiovascular or neurological symptoms
    • Grade 4 (Life-threatening): Shock, respiratory failure
Clinical ParameterGrade 1Grade 2Grade 3Grade 4
SkinLocalized urticariaGeneralized urticariaAngioedemaCyanosis
RespiratoryNormalMild wheezeSevere wheezeRespiratory arrest
CardiovascularNormalTachycardiaHypotensionShock
NeurologicalNormalAnxietyConfusionUnconscious
TreatmentAntihistamineH1+H2 blockersEpinephrineICU management
  • Anaphylaxis Management

    • First-line: Epinephrine 0.01 mg/kg IM (maximum 0.5 mg)
    • Second-line: H1 antihistamine + H2 antihistamine
    • Third-line: Corticosteroids (1-2 mg/kg prednisolone)
    • Supportive: IV fluids, oxygen, bronchodilators
  • Chronic Allergy Optimization

    • Step 1: Allergen avoidance + H1 antihistamine
    • Step 2: Double-dose H1 or add H2 antihistamine
    • Step 3: Add leukotriene antagonist
    • Step 4: Consider immunotherapy
    • Step 5: Specialist referral for refractory cases

Clinical Pearl: Component-resolved diagnostics enables precision medicine approaches, with Ara h 1/2/3 positivity predicting severe peanut reactions requiring strict avoidance, while Ara h 8 positivity suggests mild oral symptoms manageable with antihistamines.

Quality Metrics and Outcomes

  • Clinical Excellence Indicators

    • Diagnostic accuracy: >95% correlation with challenge testing
    • Treatment success: >80% symptom control at 6 months
    • Emergency preparedness: 100% high-risk patients with action plans
    • Patient satisfaction: >90% quality of life improvement
    • Safety record: Zero preventable anaphylaxis fatalities
  • Continuous Improvement Framework

    • Monthly case reviews: Diagnostic accuracy assessment
    • Annual outcome analysis: Treatment effectiveness evaluation
    • Emergency drill practice: Response time optimization
    • Patient education audits: Knowledge retention testing
    • Literature updates: Evidence-based protocol refinement

💡 Master This: Clinical mastery in allergy medicine requires systematic approach to every patient encounter, combining evidence-based protocols with individualized care that accounts for age, comorbidities, family dynamics, and psychosocial factors affecting treatment adherence and outcomes.

The expert allergist transforms complex immunological concepts into practical clinical tools that protect children, educate families, and build confidence in managing allergic diseases throughout childhood and beyond.

🎯 Clinical Mastery Arsenal: The Allergy Expert's Toolkit

Practice Questions: Immunology and Allergies

Test your understanding with these related questions

A 32 year old man presents with a 3-month history of weight loss, night sweats, a productive cough with blood-tinged sputum, anorexia, general malaise, and a low grade fever. A PPD skin test shows > 10 mm of induration. If the area of induration were biopsied, which of the following type of reactive cells would be found?

1 of 5

Flashcards: Immunology and Allergies

1/8

Patients of Reye's syndrome who have recieved IVIG should not recieve live attenuated vaccine for _____ months after IVIG administration

TAP TO REVEAL ANSWER

Patients of Reye's syndrome who have recieved IVIG should not recieve live attenuated vaccine for _____ months after IVIG administration

11

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial